CN107746426B - Amygdalus communis protein source alpha-glucosidase inhibitory peptide subjected to enzymolysis by protease Prote AX and preparation method thereof - Google Patents
Amygdalus communis protein source alpha-glucosidase inhibitory peptide subjected to enzymolysis by protease Prote AX and preparation method thereof Download PDFInfo
- Publication number
- CN107746426B CN107746426B CN201711120858.1A CN201711120858A CN107746426B CN 107746426 B CN107746426 B CN 107746426B CN 201711120858 A CN201711120858 A CN 201711120858A CN 107746426 B CN107746426 B CN 107746426B
- Authority
- CN
- China
- Prior art keywords
- protease
- prote
- enzymolysis
- alpha
- almond protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06156—Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention provides a almond protein source alpha-glucosidase inhibitory peptide which is subjected to enzymolysis by protease Prote AX, which is characterized by comprising the following components in percentage by weight: the amino acid sequence is tryptophan-histidine, and the structural formula is as follows:
the invention aims to provide a natural almond protein source alpha-glucosidase inhibitory peptide which has good effect of assisting in reducing blood sugar and is subjected to enzymolysis by protease Prote AX and a preparation method thereof.
Description
Technical Field
The invention relates to the technical field of biology, and in particular relates to a wild almond protein source alpha-glucosidase inhibitory peptide subjected to enzymolysis by protease Prote AX and a preparation method thereof.
Background
Diabetes has become one of four chronic diseases which threaten human health and are also called as cardiovascular and cerebrovascular diseases, cancers and chronic respiratory diseases. Diabetic patients generally reduce the effects of insulin resistance by ingesting insulin. However, long-term administration of insulin to patients results in impaired insulin secretion and loss of β -cells (Clark, 1998). Diabetes as a chronic disease causes great inconvenience to the normal life of patients, the patients feel tired and sleepy, and adults with serious diseases even lose labor capacity. The only way for treating diabetes is to take hypoglycemic drugs, but the hypoglycemic drugs developed at present are mainly chemical synthesis or biochemical reagents, and the drugs cannot completely cure diabetes. Therefore, researches on natural hypoglycemic drugs with small side effects are urgent. Hypoglycemic drugs are mainly classified into insulin and its analogous drugs, insulinotropic agents, insulin sensitizers, protein glycosylation inhibitors, α -glucosidase inhibitors, insulin-like growth factors, and aldose reductase inhibitors.
The alpha-glucosidase inhibitor is an effective diabetes treatment drug, can competitively inhibit the activity of various alpha-glucosidase in the small intestine, slow down the digestion of carbohydrate by the alpha-glucosidase, slow down the speed of starch decomposition into glucose and the absorption of glucose in the intestinal tract, and reduce postprandial blood sugar. The currently marketed alpha-glucosidase inhibitor drugs mainly comprise acarbose (acrbose), voglibose (voglibose) and miglitol (midlitol), but the drugs usually have side effects such as flatulence, intestinal colic, abdominal distension or diarrhea and the like when taken for a long time as prescription drugs. These drugs are non-hydrolyzed carbohydrate analogs, and have strong inhibition ability on alpha-amylase in pancreas and weak inhibition ability on alpha-glucosidase in small intestine epithelium, so that carbohydrate is absorbed in small intestine and stays in small intestine, which causes fermentation and decomposition of intestinal bacteria to generate more gas, and causes discomfort in human gastrointestinal tract.
Therefore, the research and development of the drug which has stronger alpha-glucosidase inhibition capability on the small intestine epithelium and weaker alpha-amylase inhibition capability on the pancreas secretion reduces the side effect of the alpha-glucosidase inhibitor drug on one hand, controls the postprandial blood sugar level on the other hand, and is the research and development direction of the ideal hypoglycemic drug.
The wild apricot is a traditional medicinal plant, is a high-quality plant protein source, has an amino acid composition close to the FAO standard of the world grain and agriculture organization, mainly consists of digestible metabolic protein, and has the physicochemical characteristics of typical plant protein. The almond protein after debitterizing treatment is safe and nontoxic, and can develop various biological activities and medical values beneficial to physiological health. The research on the biological active peptide of the almond protein source has wide prospect, and in recent years, scholars at home and abroad carry out deep research on the biological active peptide. The almond protein is used as a high-quality easily digestible vegetable protein and is also a good source of bioactive peptides. The amygdalus comnnis protein source alpha-glucosidase inhibitory peptide has biological activities of reducing blood sugar, reducing blood fat, reducing blood pressure, improving immunity, resisting cancer, inhibiting bacteria and the like, but the separation and purification and activity research of the amygdalus comnnis protein source alpha-glucosidase inhibitory peptide belong to the blank field at home and abroad. The invention screens out high-purity and high-activity alpha-glucosidase inhibitory peptide by systematically analyzing the antioxidant capacity of the almond protein and the almond peptide, and researches the in-vivo blood sugar reducing capacity of the almond polypeptide to obtain the almond protein source alpha-glucosidase inhibitory peptide which is subjected to enzymolysis by protease Prote AX. In the research process, the inventor firstly extracts the almond protein and an extraction process thereof, analyzes and researches the amino acid composition of the almond protein, then carries out enzymolysis on the almond protein by using protease to obtain active peptide, and researches the almond protein source alpha-glucosidase inhibitory peptide subjected to enzymolysis by using protease Prote AX.
Disclosure of Invention
The invention aims to solve the technical problem of providing a mountain almond protein source alpha-glucosidase inhibitory peptide which has good alpha-glucosidase inhibitory activity effect and is subjected to enzymolysis by protease Prote AX and a preparation method thereof.
In order to solve the technical problems, the invention provides the following technical scheme:
the almond protein source alpha-glucosidase inhibitory peptide is subjected to enzymolysis by protease Prote AX, the amino acid sequence of the almond protein source alpha-glucosidase inhibitory peptide is tryptophan-histidine, and the structural formula is as follows:
the almond protein source alpha-glucosidase inhibitory peptide subjected to enzymolysis by protease Prote AX is adopted. The actual molecular weight is 341.37 g/mol. Measured alpha-glucosidase inhibitory activity IC of peptide A50The value is 0.58 +/-0.01 mu g/mL; calculating the alpha-glucosidase inhibitory activity IC of the peptide A by taking the molecular weight as the basis and the unit of mu mol/L50The value was 16.99. + -. 0.01. mu. mol/L.
The invention also provides another technical scheme: a preparation method of amygdalin source alpha-glucosidase inhibitory peptide by protease Prote AX enzymolysis comprises the following steps,
firstly, extracting the wild almond protein by using an isoelectric point precipitation method;
secondly, preparing the almond protein zymolyte polypeptide by using protease Prote AX for enzymolysis;
and thirdly, separating and purifying the almond protein zymolyte polypeptide prepared by protease Prote AX enzymolysis to obtain the almond protein source alpha-glucosidase inhibitory peptide.
Further, in the second step, the method for preparing the almond protein zymolyte polypeptide by using protease Prote AX for enzymolysis comprises the following steps: and (3) carrying out enzymolysis on the almond protein obtained in the step one by using protease Prote AX, inactivating the enzyme for 10min after the enzymolysis, cooling, centrifuging and taking supernate to obtain enzymolysis liquid, namely the almond protein hydrolysate polypeptide.
Further, in the second step, the enzymolysis condition of the protease Prote AX is that the pH is 7.0, the temperature is 50 ℃, the substrate concentration is 50mg/mL, the mass ratio of the enzyme addition amount to the substrate is 0.02mg/mg, and the enzymolysis time is 6 h.
Further, in the third step, the method for separating and purifying the almond protein zymolyte polypeptide prepared by zymolysis of protease Prote AX comprises the following steps:
a. after the enzymolysis liquid is ultrafiltered, freeze-drying in vacuum to obtain wild almond polypeptide freeze-dried powder;
b. separating by gel chromatography;
c. separating by reversed phase high performance liquid chromatography;
d. separating by a molecular sieve;
e. purifying by reversed phase high performance liquid chromatography to obtain alpha-glucosidase inhibitory peptide.
Further, in the step a, after the enzymolysis liquid is ultrafiltered, the enzymolysis liquid with the molecular weight less than 5kDa is collected and is frozen and dried in vacuum.
Further, in the first step, in the isoelectric precipitation method,
1) adding deionized water into defatted almond meal powder according to a liquid-to-material ratio to prepare a almond protein solution;
2) dissolving out the protein of the sample by ultrasonic wave, adjusting the pH and temperature of the reaction solution, and stirring and extracting;
3) after extraction, taking a leaching solution for centrifugation, and collecting supernatant;
4) adjusting the pH of the supernatant to the isoelectric point of the almond protein by using 1mol/L HCl, centrifuging, removing the supernatant, and collecting the precipitate;
5) re-dissolving the precipitate with deionized water, adjusting pH of the solution, and freeze drying to obtain almond protein.
Further, in the step one 2), the extraction temperature is 37 ℃, the extraction time is 60min, the pH is 9.0, and in the step one 1), the liquid-material ratio is 14 mL/g.
Further, in the step 4), the isoelectric point of the amygdalin is pI 4.1.
Drawings
FIG. 1 shows the alpha-glucosidase inhibitory activity of the enzymatic hydrolysate obtained by enzymatic hydrolysis of amygdalus communis protein with different enzymes.
FIG. 2 is a Sephadex G-25 gel chromatography chromatogram of 0-5 kDa component of protease Prote AX enzymolysis solution.
FIG. 3 is a reversed-phase high performance liquid chromatogram of the P3 component of the protease Prote AX enzymolysis liquid.
FIG. 4 is a molecular sieve chromatogram of P3P2 fraction separated from protease Prote AX enzymolysis solution.
FIG. 5 is a high performance liquid chromatography purification chromatogram of a separation peak of a protease Prote AX enzymatic hydrolysate.
FIG. 6 is a mass spectrum of protease Prote AX zymolytic peptide (A).
FIG. 7 is a Trp-His reversed phase high performance liquid chromatogram (simulated prior to digestion).
FIG. 8 is a Trp-His reversed phase high performance liquid chromatogram (after simulated digestion).
Detailed Description
The invention relates to a wild almond protein source alpha-glucosidase inhibitory peptide enzymolyzed by protease Prote AX, which has the specific implementation mode that: the preparation method comprises the following steps:
firstly, extracting the wild almond protein by using an isoelectric point precipitation method;
1) taking defatted almond meal powder (screened by a 60-mesh sieve), and adding deionized water according to the liquid-material ratio of 14mL/g to prepare a almond protein solution;
2) performing ultrasonic treatment for 10min under cell disruptor to dissolve out protein, adjusting pH of the reaction solution to 9.0 and temperature to 37 deg.C, stirring at 50r/min for 60min to extract almond protein; adjusting the pH of the solution by using 1mol/L NaOH or 1mol/L HCl to maintain the pH of the solution at 9.0;
3) after extraction, centrifuging at 4000r/min at 4 ℃ for 20min, and collecting supernatant;
4) adjusting the pH of the supernatant to isoelectric point pI 4.1 of the almond protein by using 1mol/L HCl, centrifuging at 4 ℃ for 15min at 5000r/min, discarding the supernatant, and collecting the precipitate;
5) redissolving the precipitate with deionized water, adjusting the pH of the solution to 9.0, rapidly freeze-drying to obtain the almond protein, and storing at-20 deg.C for use.
Secondly, hydrolyzing the almond protein by using protease Prote AX to prepare almond protein hydrolysate polypeptide;
carrying out enzymolysis on the almond protein obtained in the step one by using protease Prote AX, wherein the enzymolysis condition is that the pH is 6.0, the temperature is 50 ℃, the substrate concentration is 50mg/mL, the mass ratio of the enzyme addition amount to the substrate is 0.02mg/mg, and the enzymolysis time is 6 h;
protease Prote AX (amantadine wild enzyme preparation trade company, a special enzyme preparation for hydrolyzing proteins rich in amino acids, which is prepared from Aspergillus oryzae by a special fermentation process, has an activity of more than or equal to 1250U/g, and has higher enzyme activity than protease preparations of other fungi).
② enzyme is inactivated for 10min after enzymolysis, supernatant fluid is taken after cooling and centrifugation to obtain enzymolysis liquid, namely the wild almond protein zymolyte polypeptide.
According to experimental research:
single factor test of time: 10g of almond protein powder is added into 200mL of deionized water to prepare the almond protein solution. Adding 150mg protease Prote AX into the almond protein solution, keeping the whole pH stable at 7.0 during enzymolysis, keeping the temperature at 60 ℃, and respectively recording the total consumption amount of 1mol/L NaOH when the enzymolysis time is 0min, 30min, 1h, 2h, 3h, 4h, 6h, 8h, 10h, 12h and 24 h.
Single factor experiment of enzyme addition: dissolving 1g of almond protein powder in 20mL of deionized water to prepare almond protein solution, adding 5mg, 10mg, 15mg, 20mg and 25mg of protease Prote AX respectively, keeping the pH value of a reaction system at 7.0 and the temperature at 60 ℃, carrying out enzymolysis for 5h, and calculating the hydrolysis degree of the almond protein solution under each condition respectively.
According to the orthogonal test, the following can be determined: the optimal enzymolysis conditions of the protease Prote AX are pH neutrality, temperature of 50 ℃, substrate concentration of 50mg/mL, enzyme addition amount of 0.02 (mass ratio of enzyme addition amount to substrate, mg/mg) and enzymolysis time of 6-8 h. Orthogonal experiments of protease Prote AX enzymatic hydrolysis show that the optimal enzymatic hydrolysis conditions are as follows: the temperature is 50 ℃, the pH value is 6.0, and the time is 6 h. The degree of hydrolysis was 26.95%.
Separating and purifying the almond protein zymolyte polypeptide prepared by protease Prote AX enzymolysis to obtain almond protein source alpha-glucosidase inhibitory peptide, which comprises the following specific steps:
a. after the enzymolysis liquid is ultrafiltered, collecting the enzymolysis liquid with the molecular weight less than 5kDa, and carrying out vacuum freeze drying to obtain wild almond polypeptide freeze-dried powder;
and (3) filtering the enzymolysis liquid in the step (II) by using a water-phase 0.45-micrometer microporous filter membrane, selecting a Pellicon Biomax filter membrane with the molecular weight of 5kDa to carry out molecular weight interception on a Millipore Labscale TFF system (4 ℃, 6000g), and collecting filtrate and residual liquid to finally obtain the product with the molecular weight of 0-5 kDa. And (4) rapidly carrying out vacuum freeze-drying on the enzymolysis liquid obtained by ultrafiltration to obtain wild almond polypeptide freeze-dried powder, and storing the wild almond polypeptide freeze-dried powder at the temperature of-20 ℃ for later use.
b. Separating by gel chromatography;
pretreatment of sephadex: filtering deionized water with 0.22 μm water system microporous membrane, and ultrasonic degassing for 2 hr. 25G of Sephadex G-25Medium particles were dissolved in 400mL deionized water, swollen at room temperature until the gel volume did not increase, then washed repeatedly with deionized water until free of impurities, and stored at 4 ℃ until use.
Filling a sephadex column: the specification of the chromatographic column (1.6cm multiplied by 60cm) is cleaned by deionized water before use. Fixing a chromatographic column, slowly adding deionized water, closing an outlet end when the liquid level is about one fourth of the height of the column, slowly adding sephadex into the chromatographic column, continuously stirring the colloid in the column in the whole process to prevent gel from settling and layering, opening a sample outlet of the chromatographic column when the gel deposition reaches more than 1cm, continuously pouring the sephadex until the distance from the top end of the chromatographic column is 5cm, and finally balancing the chromatographic column by deionized water with 3-5 column volumes until the liquid level of the sephadex does not drop any more. The whole operation process needs to be slowly continued, and the generation of bubbles is prevented.
Sample introduction, elution and collection: the sample was dissolved in a neutral Tris-HCl solution (10mmol/L pH7.0, containing 150mmol/L NaCl, filtered through a 0.22 μm organic phase microporous membrane and degassed) to prepare a sample solution with a solubility of 100 mg/mL. Wherein, the mobile phase is Tris-HCl solution, and the flow rate is as follows: 1mL/min, and the automatic collector is set to collect one tube of separation liquid every 5 min.
Collecting the components, freeze-drying, respectively measuring the inhibition rate of alpha-glucosidase of each component, selecting the components with higher inhibition capacity, and further separating by high performance liquid chromatography.
c. Separating by reversed phase high performance liquid chromatography;
dissolving the separated high-activity lyophilized powder in 0.6mL of 0.06% trifluoroacetic acid TFA aqueous solution, centrifuging at 1200rpm for 10min, collecting supernatant, degassing for 10min by ultrasonic treatment, filtering with 0.22 μm organic phase microporous membrane, and filtering with 0.6 μm organic phase microporous membrane
Systematic separation, and the chromatographic column is a Zorbax SB-C18 reversed-phase high performance liquid chromatographic column (4.6mm multiplied by 250mm, 5 μm). Flow ofMobile phase a (0.06% trifluoroacetic acid in water) was equilibration buffer and mobile phase B (0.05% trifluoroacetic acid in acetonitrile) was elution buffer. The elution gradient of separation and purification is that the mobile phase B is at least 0.2CV from 50 percent to 100 percent by at least 5 Column Volumes (CV). The sample was taken at 500. mu.L, a flow rate of 0.8mL/min, and fractions were detected and collected at 280 nm. Measuring the inhibition rate of each component of alpha-glucosidase, vacuum freeze drying the component with high inhibition ability, and storing at-20 deg.C for use.
d. Separating by a molecular sieve;
dissolving the separated high-activity lyophilized powder in 1mL of 20mmol/L PBS buffer solution (pH7.0), centrifuging at 1200rpm for 10min, collecting supernatant, ultrasonic degassing for 10min, filtering with 0.22 μm organic phase microporous membrane, and filtering with a filter
And (5) separating the system. The column of the molecular sieve is SuperdexTMPeptide 10/300GL (10 mm. times.300 mm). The equilibration buffer was 20mmol/L PBS buffer (pH7.0), the flow rate was 0.5mL/min, the sample volume was 100. mu.L, the elution gradient was 2CV with equal gradient, and the peak was detected and collected at 280 nm.
e. And (4) continuously purifying by using reverse phase high performance liquid chromatography to obtain the alpha-glucosidase inhibitory peptide.
And (3) continuously purifying the separated high-activity almond polypeptide freeze-dried powder by using reverse phase high performance liquid chromatography to further obtain the high-purity high-activity alpha-glucosidase inhibitory peptide.
Fifth, study of experiments
Experimental study
1) Research on inhibition effect of alpha-glucosidase inhibitory peptide of amygdalus communis protein enzymolysis product of three enzymes
Selecting almond protein enzymolysis products of three enzymes of protease M, Prote AX and Alcalase with strong oxidation resistance to carry out the determination of the inhibition activity of the alpha-glucosidase. The three enzyme hydrolysate freeze-dried powders are respectively prepared into different concentrations: 0.5mg/mL, 1mg/mL, 2mg/mL, 3mg/mL, 4mg/mL, 5mg/mL, 6mg/mL, 8mg/mL, 10mg/mL, and the alpha-glucosidase inhibition rates were measured, respectively. The concentration of the wild almond polypeptide is used as an abscissa, and the alpha-glucosidase inhibition rate is used as an ordinate to construct a graph, as shown in fig. 1, the three enzymatic hydrolysis products all have certain alpha-glucosidase inhibition rates, the alpha-glucosidase inhibition capacities of the various enzymatic hydrolysis products are increased to different degrees along with the increase of the concentration of the wild almond polypeptide, wherein the enzymatic hydrolysis product effect of the Alcalase protease is more prominent, and when the concentration is 10mg/mL, the alpha-glucosidase inhibition rate of the enzymatic hydrolysis liquid reaches 33.95%; the enzymolysis product of the protease M has weaker effect than other two groups, but the alpha-glucosidase inhibition rate can also reach 15.98% when the concentration is 10 mg/mL.
2) Molecular weight condition study on separation and purification of high-purity protease Prote AX enzymatic hydrolysate
An enzymolysis liquid obtained by protease Prote AX enzymolysis adopts a Millipore Labscale TFF system and is ultrafiltered by three Pellicon Biomax filter membranes of 30kDa, 10kDa and 5kDa to obtain four components of more than 30kDa, 10kDa to 30kD, 5kDa to 10kD and 0kDa to 5kD, the alpha-glucosidase inhibition rate is respectively determined, and IC of the alpha-glucosidase inhibition rate is used as the IC of the alpha-glucosidase inhibition rate50The values serve as comparative indicators. The alpha-glucosidase inhibition activity of protease protate AX enzymolysis liquid with different molecular weights (0-5 kDa, 5-10 kDa and 10-30 kDa) is shown in the following table 1:
TABLE 1 glucosidase inhibitory activity of protease protate AX hydrolysates of different molecular weights (0-5 kDa, 5-10 kDa and 10-30 kDa)
| Molecular weight (kDa) | IC50/(mg/mL) |
| >30 | 18.29±0.03 |
| 10～30 | 16.91±0.01 |
| 5～10 | 5.48±0.02 |
| 0～5 | 2.08±0.01 |
As can be seen from the data in Table 1, the protease protate AX enzymolysis solution with the molecular weight range of 0-5 kDa has stronger alpha-glucosidase inhibition capability. Therefore, the 0-5 kDa component is selected for Sephadex G-25Medium gel chromatography separation.
As shown in FIG. 2, the Sephadex G-25 gel chromatography chromatogram of 0-5 kDa component of protease Prote AX enzymolysis solution has three main absorption peaks marked as P1, P2 and P3 at 280nm, as can be seen from FIG. 2; the alpha-glucosidase inhibitory activity of 0-5 kDa component separation peak of protease Prote AX enzymolysis liquid is shown in table 2:
TABLE 2 alpha-glucosidase inhibitory activity of 0-5 kDa component separation peak of protease Prote AX enzymatic hydrolysate
| Components | IC50/(mg/mL) |
| P1 | 2.133±0.022 |
| P2 | 1.285±0.0014 |
| P3 | 0.097±0.004 |
As can be seen from Table 2, among them, P3 has the strongest α -glucosidase inhibitory ability, and its α -glucosidase inhibitory rate IC50The value was 0.097. + -. 0.004 mg/mL.
Therefore, the gel chromatography chromatographic peak P3 has the strongest activity, so that the P3 component is collected and further separated by using a Zorbax SB-C18 reversed-phase high performance liquid chromatography column to obtain a chromatogram map 3. As can be seen from FIG. 3, four main absorption peaks, labeled P3P1, P3P2, P3P3 and P3P4, were obtained after P3 was isolated by the AKTA system. The alpha-glucosidase inhibition rates were measured for four fractions separated by reverse phase HPLC, respectively, as shown in Table 3, where the fraction with higher activity was P3P2 (IC)50＝0.0074±0.0003mg/mL)。
TABLE 3 alpha-glucosidase inhibitory activity of P3 fraction isolated from protease Prote AX enzymatic hydrolysate
| Components | IC50/(mg/mL) |
| P3P1 | 0.0964±0.0021 |
| P3P2 | 0.0074±0.0003 |
| P3P3 | 0.0861±0.0013 |
| P3P4 | 0.0104±0.0006 |
The main peak P3P2 was collected and further separated by molecular sieve and the resulting chromatogram was shown in fig. 4, in which the main peak was marked a. Collecting peak a, purifying by reversed phase high performance liquid chromatography to obtain high purity chromatographic peak A, and measuring its alpha-glucosidase inhibitory activity IC as shown in FIG. 550The value was 0.58. + -. 0.01. mu.g/mL, and the high purity and high activity α -glucosidase inhibitory peptide was labeled A.
Sixthly, the mass spectrum and the amino acid sequence analysis of the alpha-glucosidase inhibitory peptide obtained by the invention
The mass spectrum result of the high-activity amygdalin source alpha-glucosidase inhibitory peptide A obtained by the enzymolysis of protease Prote AX is shown in figure 6, and the predicted molecular weight is as follows: 342.30 g/mol. Through N-terminal amino acid sequence analysis, the amino acid sequence of the peptide A is tryptophan-histidine (Trp-His), and the structural formula is shown as follows:
the actual molecular weight is 341.37 g/mol. Measured alpha-glucosidase inhibitory activity IC of peptide A50The value is 0.58 +/-0.01 mu g/mL; calculating the alpha-glucosidase inhibitory activity IC of the peptide A by taking the molecular weight as the basis and the unit of mu mol/L50The value was 16.99. + -. 0.01. mu. mol/L.
Seventhly, the method comprises the following steps: alpha-glucosidase inhibitory peptide mimetic digestion stability assay
Pepsin and trypsin are selected to perform stability determination of simulated digestion environment on 4 newly obtained alpha-glucosidase inhibitory peptides, and the alpha-glucosidase inhibitory activity, peak area and retention time of each inhibitory peptide before and after digestion are determined by adopting reverse phase high performance liquid chromatography. The measurement results are shown in fig. 7 and 8: FIGS. 7 and 8 show the chromatograms of Trp-His before and after digestion, and the specific measurement results of each index are shown in Table 4,
TABLE 4 stability of Trp-His, peptide A before and after simulated digestion
| Trp-His | IC50/(μmol/L) | Peak area/(μ V s) | Retention time/min |
| Before digestion | 16.99±0.01 | 3958798 | 12.17 |
| After digestion | 17.08±0.05 | 3954779 | 12.03 |
It can be seen that the peptide A Trp-His has slightly different retention time and alpha-glucosidase inhibitory activity by simulating the peak area before and after digestion of gastrointestinal fluids by pepsin and trypsin. The result shows that the amygdalin alpha-glucosidase inhibitory peptide enzymolyzed by the protease Prote AX can still keep good stability and activity after the peptide A Trp-His is subjected to simulated in vivo digestion.
The amino acid sequence table of Trp-His amino acid in the almond protein source alpha-glucosidase inhibitory peptide subjected to protease M enzymolysis is as follows:
<110> Chongqing three gorges college
<120> amygdalin alpha-glucosidase inhibitory peptide obtained by enzymolysis of protease Prote AX and preparation method thereof
<160>1
<210>1
<211>2
<212>PRT
<213>Artificial
<220>
<223> alpha-glucosidase inhibitory peptide
<400>1
Trp-His。
It will be apparent to those skilled in the art that various changes and modifications can be made without departing from the structure of the invention, and it is intended to cover all modifications and equivalents of the invention without departing from the spirit and scope of the invention.
<110> Chongqing three gorges college
<120> amygdalin alpha-glucosidase inhibitory peptide obtained by enzymolysis of protease Prote AX and preparation method thereof
<160>1
<210>1
<211>2
<212>PRT
<213>Artificial
<220>
<223> alpha-glucosidase inhibitory peptide
<400>1
Trp-His
Claims (6)
1. A preparation method of almond protein source alpha-glucosidase inhibitory peptide subjected to enzymolysis by protease Prote AX is characterized by comprising the following steps: comprises the following steps of (a) carrying out,
firstly, extracting the wild almond protein by using an isoelectric point precipitation method;
secondly, hydrolyzing the almond protein by using protease Prote AX to prepare almond protein hydrolysate polypeptide;
separating and purifying the almond protein zymolyte polypeptide prepared by protease Prote AX enzymolysis to obtain almond protein source alpha-glucosidase inhibitory peptide, wherein the sequence of the inhibitory peptide is tryptophan-histidine;
in the second step, the method for preparing the almond protein zymolyte polypeptide by using protease Prote AX for enzymolysis comprises the following steps: carrying out enzymolysis on the almond protein obtained in the step one by using protease Prote AX, inactivating the enzyme for 10min after the enzymolysis, cooling, centrifuging and taking supernate to obtain enzymolysis liquid, namely the almond protein hydrolysate polypeptide;
the enzymolysis condition of the protease Prote AX is that the pH is 6.0, the temperature is 50 ℃, the substrate concentration is 50mg/mL, the mass ratio of the enzyme addition amount to the substrate is 0.02mg/mg, and the enzymolysis time is 6 h;
the amino acid sequence of the almond protein source alpha-glucosidase inhibitory peptide is tryptophan-histidine, and the structural formula is as follows:
2. the method of preparing a amygdalin-derived alpha-glucosidase inhibitory peptide enzymatically hydrolyzed with protease Prote AX according to claim 1, wherein: in the third step, the method for separating and purifying the almond protein zymolyte polypeptide prepared by zymolysis of protease Prote AX comprises the following steps:
a. after the enzymolysis liquid is ultrafiltered, freeze-drying in vacuum to obtain wild almond polypeptide freeze-dried powder;
b. separating by gel chromatography;
c. separating by reversed phase high performance liquid chromatography;
d. separating by a molecular sieve;
e. purifying by reversed phase high performance liquid chromatography to obtain alpha-glucosidase inhibitory peptide.
3. The method of preparing a amygdalin-derived alpha-glucosidase inhibitory peptide enzymatically hydrolyzed with protease Prote AX according to claim 2, wherein: in the step a, after the enzymolysis liquid is ultrafiltered, the enzymolysis liquid with the molecular weight less than 5kDa is collected and is frozen and dried in vacuum.
4. The method of claim 3, wherein the preparation of the amygdalin-derived alpha-glucosidase inhibitory peptide enzymatically hydrolyzed with protease Prote AX comprises: in the first step, in the isoelectric point precipitation method,
1) adding deionized water into defatted almond meal powder according to a liquid-to-material ratio to prepare a almond protein solution;
2) dissolving out the protein of the sample by ultrasonic wave, adjusting the pH and temperature of the reaction solution, and stirring and extracting;
3) after extraction, taking a leaching solution for centrifugation, and collecting supernatant;
4) adjusting the pH of the supernatant to the isoelectric point of the almond protein by using 1mol/L HCl, centrifuging, removing the supernatant, and collecting the precipitate;
5) re-dissolving the precipitate with deionized water, adjusting pH of the solution, and freeze drying to obtain almond protein.
5. The method of preparing a amygdalin-derived alpha-glucosidase inhibitory peptide enzymatically hydrolyzed with protease Prote AX according to claim 4, wherein: in the step one 2), the extraction temperature is 37 ℃, the extraction time is 60min, the pH is 9.0, and in the step one 1), the liquid-material ratio is 14 mL/g.
6. The method of claim 5, wherein the preparation of the amygdalin-derived alpha-glucosidase inhibitory peptide enzymatically hydrolyzed using protease Prote AX comprises: in the step 4), the isoelectric point of the almond protein is pI 4.1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711120858.1A CN107746426B (en) | 2017-11-14 | 2017-11-14 | Amygdalus communis protein source alpha-glucosidase inhibitory peptide subjected to enzymolysis by protease Prote AX and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711120858.1A CN107746426B (en) | 2017-11-14 | 2017-11-14 | Amygdalus communis protein source alpha-glucosidase inhibitory peptide subjected to enzymolysis by protease Prote AX and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107746426A CN107746426A (en) | 2018-03-02 |
| CN107746426B true CN107746426B (en) | 2020-12-01 |
Family
ID=61251067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711120858.1A Active CN107746426B (en) | 2017-11-14 | 2017-11-14 | Amygdalus communis protein source alpha-glucosidase inhibitory peptide subjected to enzymolysis by protease Prote AX and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107746426B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113549666B (en) * | 2021-07-28 | 2023-06-13 | 新疆农业大学 | Almond prolamin alpha-glucosidase inhibitory peptide and preparation method and application thereof |
| CN114716523B (en) * | 2022-04-15 | 2023-05-23 | 中国农业大学 | Millet prolamin peptides with alpha-glucosidase inhibitory activity |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103539831A (en) * | 2013-09-29 | 2014-01-29 | 北京林业大学 | Prunus armeniaca alpha-glucosidase inhibiting peptide as well as preparation method and application of inhibiting peptide |
| EP3012264B1 (en) * | 2013-06-10 | 2020-03-18 | Suntory Holdings Limited | Plant extract containing diketopiperazine and method for producing same |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6523647B2 (en) * | 2013-11-14 | 2019-06-05 | 大谷 勝 | Method for producing banana-derived composition |
-
2017
- 2017-11-14 CN CN201711120858.1A patent/CN107746426B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3012264B1 (en) * | 2013-06-10 | 2020-03-18 | Suntory Holdings Limited | Plant extract containing diketopiperazine and method for producing same |
| CN103539831A (en) * | 2013-09-29 | 2014-01-29 | 北京林业大学 | Prunus armeniaca alpha-glucosidase inhibiting peptide as well as preparation method and application of inhibiting peptide |
Non-Patent Citations (2)
| Title |
|---|
| The Anti-atherosclerotic Dipeptide, Trp-His, Reduces Intestinal Inflammation through the Blockade of L-Type Ca2+ Channels;Yutaro Kobayashi et al.;《J. Agric. Food Chem》;20150616;第63卷(第26期);摘要 * |
| 山杏仁蛋白源α-葡萄糖苷酶抑制肽的分离、纯化及鉴定;顾欣等;《中国粮油学报》;20160831;第31卷(第8期);第116-121页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107746426A (en) | 2018-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107698659B (en) | Amygdalus sinica protein source alpha-glucosidase inhibitory peptide subjected to enzymolysis by protease M and preparation method thereof | |
| CN104004806B (en) | One kind has anticoagulation and thrombus dissolving earthworm polypeptide and its enzymolysis preparation and application | |
| US20150175991A1 (en) | Bacillus, hyaluronidase, and uses thereof | |
| CN103539831B (en) | Ansu apricot alpha-glucosaccharase enzyme inhibition peptide and its production and use | |
| CN101012285B (en) | Oyster polysaccharide, preparing method and its application in preparing cosmetics | |
| CN104131055B (en) | Preparation method for phycoerythrin ACE inhibitory peptide | |
| CN103539833B (en) | High reactivity alpha-glucosaccharase enzyme inhibition peptide and its production and use | |
| CN107746426B (en) | Amygdalus communis protein source alpha-glucosidase inhibitory peptide subjected to enzymolysis by protease Prote AX and preparation method thereof | |
| CN103923201A (en) | Preparation method of hippocampus active glycoprotein | |
| CN115772550A (en) | Preparation method of straw mushroom polypeptide with antioxidant activity and liver protection effect | |
| WO2021082294A1 (en) | Preparation of and method for immunomodulatory peptide | |
| CN107541533A (en) | A kind of preparation method of medicine food hypha polysaccharide polypeptide immunopotentiator | |
| CN109608557A (en) | Polysaccharides extracts Isolation and purification method, Lycium chinense glycopeptide and preparation method | |
| CN105085651B (en) | A kind of casein phosphopeptide monomer and preparation method thereof | |
| CN112501229B (en) | Production process of bovine bone collagen peptide | |
| CN109369783A (en) | A kind of polypeptide RDP1 and its method of purification and application | |
| CN115536731A (en) | Preparation method of high-activity mung bean albumin glycopeptide-lowering | |
| CN116375902A (en) | Grape residue polysaccharide for improving immune function and preparation method and application thereof | |
| CN115124591A (en) | Spirulina platensis phycocyanin angiotensin converting enzyme inhibitory peptide and preparation method and application thereof | |
| CN115109117A (en) | Multicladium algae phycoerythrin angiotensin converting enzyme inhibitory peptide and preparation method and application thereof | |
| CN114250216B (en) | Nattokinase separation and purification method | |
| CN107529533A (en) | One kind can be self-assembled into the pH sensitivities polypeptide of hydrogel and its as the application for loading drug material | |
| CN105803024B (en) | A method of ace inhibitory peptide is prepared using coconut cake globulin as raw material | |
| CN101580846A (en) | Human cytoglobin for preventing and curing cirrhosis and preparation method thereof | |
| CN114032267A (en) | Preparation method and application of active peptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220714 Address after: 215000 room 1018-01, building 23, Times Square, Suzhou Industrial Park, Suzhou area, China (Jiangsu) pilot Free Trade Zone, Suzhou, Jiangsu Province Patentee after: Suzhou Treasure Box Technology Co.,Ltd. Address before: No.780, No.2, salon Road, Wanzhou District, Chongqing Patentee before: CHONGQING THREE GORGES University Effective date of registration: 20220714 Address after: 510670 Room 203, building 3, No. 9 Xiangshan Road, Huangpu District, Guangzhou, Guangdong Province (office only) Patentee after: Guangdong baioufei silk Cell Research Center Co.,Ltd. Address before: 215000 room 1018-01, building 23, Times Square, Suzhou Industrial Park, Suzhou area, China (Jiangsu) pilot Free Trade Zone, Suzhou, Jiangsu Province Patentee before: Suzhou Treasure Box Technology Co.,Ltd. |
|
| TR01 | Transfer of patent right |